Laurence Klotz MD, FRCS(C)Professor of Surgery, University of Toronto, Toronto, Ontario, Canada
Laurence Klotz, MD is the past Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He is also Chairman of the World Uro-Oncology Federation and a past president of the Urological Research Society and the Canadian Urological Association. Dr. Klotz was the Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal, and is now Editor Emeritus of the CUAJ. He was the founder and is chairman of the Canadian Urology Research Consortium.
Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. Dr. Klotz continued his postgraduate studies with a special fellowship at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology and tumour biology.
Dr. Klotz is a widely published uro-oncologist with over 300 publications and 4 books. His main research interest has been prostate cancer. He serves on the boards of many medical/scientific organizations and journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases, Brazilian Journal of Urology, Italian Journal of Urology, and World Journal of Urology. He was recently awarded the Queen’s Jubilee Medal for meritorious public service.
Recent Contributions to PracticeUpdate:
- Rates of Primary and Secondary Treatments for Patients on Active Surveillance for Localized Prostate Cancer
- Risk of Metastasis in Men With Grade Group 2 Prostate Cancer Managed With Active Surveillance
- Long-Term Outcomes of Active Surveillance for Prostate Cancer: The MSKCC Experience
- Association of Gleason Grade With ADT Duration and Survival Outcomes
- Reasons for Discontinuing Active Surveillance
- PSA Kinetics Predicts Prostate Cancer Active Surveillance Outcomes
- The Diverse Genomic Landscape of Clinically Low-Risk Prostate Cancer
- Anterior Zone Biopsy in Men on Active Surveillance for Prostate Cancer
- Patients With Intermediate-Risk Prostate Cancer May Be Good Candidates for Active Surveillance: Pro
- Patients With Intermediate-Risk Prostate Cancer May Be Good Candidates for Active Surveillance: Con